Ten Years of Kidney Paired Donation at Mayo Clinic: The Benefits of Incorporating ABO/HLA Compatible Pairs.
ABO Blood-Group System
/ immunology
Adult
Aged
Altruism
Donor Selection
/ methods
Female
Graft Rejection
/ epidemiology
HLA Antigens
/ immunology
Histocompatibility Testing
/ statistics & numerical data
Humans
International Cooperation
Kidney Failure, Chronic
/ blood
Kidney Transplantation
/ adverse effects
Living Donors
/ psychology
Male
Middle Aged
Retrospective Studies
Time Factors
Time-to-Treatment
/ statistics & numerical data
Transplant Recipients
/ psychology
Treatment Outcome
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
7
9
2019
medline:
7
10
2020
entrez:
7
9
2019
Statut:
ppublish
Résumé
We examined the 10-year experience of Mayo Clinic's kidney paired donation (KPD).We aimed to determine the benefits for the recipients of enrolled ABO/HLA compatible pairs and determine the factors associated with prolonged KPD waiting time. We performed a retrospective study of 332 kidney transplants facilitated by the Mayo 3-site KPD program from September 2007 to June 2018. The median (interquartile range) time from KPD entry to transplantation was 89 days (42-187 days). The factors independently associated with receiving a transplant >3 months after KPD entry included recipient blood type O and calculated panel reactive antibodies ≥98%. Fifty-four ABO/HLA compatible pairs participated in KPD for the following reasons: cytomegalovirus mismatch (18.5% [10/54]), Epstein-Barr virus (EBV) mismatch (EBV) (9.3% [5/54]), age/size mismatch (51.9% [28/54]), or altruistic reasons (20.3% [11/54]). Cytomegalovirus and EBV mismatch were avoided in 90% (9/10) and 100% (5/5) of cases. Recipients who entered KPD for age/size mismatch and altruistic reasons received kidneys from donors with lower Living Kidney Donor Profile Index scores than their actual donor (median [interquartile range] 31.5 [12.3-47]; P < 0.001 and 26 (-1 to 46); P = 0.01 points lower, respectively). Median time to transplant from KPD entry for compatible pair recipients was 70 days (41-163 days), and 44.4% (24/54) of these transplants were preemptive. All chains/swaps incorporating compatible pairs included ABO/HLA incompatible pairs. KPD should be considered for all living donor/recipient pairs because the recipients of these pairs can derive personal benefit from KPD while increasing the donor pool for difficult to match pairs.
Sections du résumé
BACKGROUND
We examined the 10-year experience of Mayo Clinic's kidney paired donation (KPD).We aimed to determine the benefits for the recipients of enrolled ABO/HLA compatible pairs and determine the factors associated with prolonged KPD waiting time.
METHODS
We performed a retrospective study of 332 kidney transplants facilitated by the Mayo 3-site KPD program from September 2007 to June 2018.
RESULTS
The median (interquartile range) time from KPD entry to transplantation was 89 days (42-187 days). The factors independently associated with receiving a transplant >3 months after KPD entry included recipient blood type O and calculated panel reactive antibodies ≥98%. Fifty-four ABO/HLA compatible pairs participated in KPD for the following reasons: cytomegalovirus mismatch (18.5% [10/54]), Epstein-Barr virus (EBV) mismatch (EBV) (9.3% [5/54]), age/size mismatch (51.9% [28/54]), or altruistic reasons (20.3% [11/54]). Cytomegalovirus and EBV mismatch were avoided in 90% (9/10) and 100% (5/5) of cases. Recipients who entered KPD for age/size mismatch and altruistic reasons received kidneys from donors with lower Living Kidney Donor Profile Index scores than their actual donor (median [interquartile range] 31.5 [12.3-47]; P < 0.001 and 26 (-1 to 46); P = 0.01 points lower, respectively). Median time to transplant from KPD entry for compatible pair recipients was 70 days (41-163 days), and 44.4% (24/54) of these transplants were preemptive. All chains/swaps incorporating compatible pairs included ABO/HLA incompatible pairs.
CONCLUSIONS
KPD should be considered for all living donor/recipient pairs because the recipients of these pairs can derive personal benefit from KPD while increasing the donor pool for difficult to match pairs.
Identifiants
pubmed: 31490859
doi: 10.1097/TP.0000000000002947
pmc: PMC7359217
mid: NIHMS1600011
pii: 00007890-202006000-00024
doi:
Substances chimiques
ABO Blood-Group System
0
HLA Antigens
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1229-1238Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK123313
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002379
Pays : United States
Références
Am J Transplant. 2015 Jun;15(6):1484-9
pubmed: 25773372
Transplantation. 2017 Mar;101(3):642-648
pubmed: 27077598
Clin Transpl. 2013;:235-9
pubmed: 25095513
Nephrol Dial Transplant. 2011 Jul;26(7):2091-9
pubmed: 21454351
Int Urol Nephrol. 2014 Jul;46(7):1441-6
pubmed: 24526331
Transplant Direct. 2016 Jun 06;2(7):e85
pubmed: 27830179
Transplant Proc. 2012 Jan;44(1):270-2
pubmed: 22310630
Clin J Am Soc Nephrol. 2017 Apr 3;12(4):669-676
pubmed: 28360198
Clin Transplant. 2013 Nov-Dec;27(6):838-43
pubmed: 23991890
Am J Transplant. 2017 Oct;17(10):2745-2746
pubmed: 28834177
Nephrol Dial Transplant. 2012 Jul;27(7):2971-9
pubmed: 22273720
Am J Transplant. 2011 Jun;11(6):1279-86
pubmed: 21564530
Am J Transplant. 2016 Jul;16(7):2077-84
pubmed: 26752290
Transplantation. 2014 Aug 15;98(3):300-5
pubmed: 24699400
Am J Transplant. 2017 Jul;17(7):1723-1728
pubmed: 28321984
Am J Transplant. 2019 Feb;19(2):573-584
pubmed: 30431703
Am J Transplant. 2012 Nov;12(11):3031-8
pubmed: 22900931
Transpl Int. 2013 May;26(5):493-501
pubmed: 23384401
Am J Transplant. 2012 Aug;12(8):2125-32
pubmed: 22548839
Clin Transplant. 2017 Jun;31(6):
pubmed: 28342273
Am J Transplant. 2018 Nov;18(11):2730-2738
pubmed: 29603640
Transplantation. 2007 Jul 27;84(2):137-43
pubmed: 17667803
Am J Transplant. 2010 Mar;10(3):449-57
pubmed: 20121749